Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Astellas Submits New Drug Application for Zolbetuximab in Japan
Astellas Pharma has announced the submission of a New Drug Application (NDA) on June 9, […]
Fujitsu launches Cloud-based Platform for Healthcare in Japan
Fujitsu today announced the launch of a new cloud-based platform that allows users to securely […]
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
Incyte today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved […]
Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application
Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing […]
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
VectivBio, a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, and Asahi […]
BioArctic: Lecanemab Receives Priority Review Status in Japan
BioArctic AB’s partner Eisai has announced that the application for manufacturing and marketing approval for […]
Nogra Pharma Announces Out-licensing Agreement with Torii Pharmaceutical for Japan for New Chemical Entity Topical Acne Treatment
Nogra Pharma, a clinical-stage biotechnology company developing innovative therapeutics for immune-inflammatory-mediated diseases, today announces it […]
Aculys Pharma and Four H Initiate Research Collaboration using Wearable Devices to Study Sleep Disorders in Japan
Aculys Pharma, a company focused on the development and commercialization of new innovative drugs in […]
KKR to Acquire Bushu Pharmaceuticals
KKR, a leading global investment firm, and Bushu Pharmaceuticals have announced the signing of definitive […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more